Compare Ascendis Pharma A/S (ASND) vs SOLAI Limited (SLAI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs SOLAI Limited — how do they compare? Ascendis Pharma A/S trades at $265.33 (market cap $17.74B), while SOLAI Limited trades at $3.24 (market cap $15.52M). The key difference: Ascendis Pharma A/S is far larger — about 1143× SOLAI Limited's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, SOLAI Limited nearer its low. Which is the better fit depends on your goals.
| ASND | SLAI | |
|---|---|---|
Market Cap | $17.74B | $15.52M |
Sector | Health | Technology |
52-Week High | $277.18 | $30.66 |
52-Week Low | $163.32 | $2.74 |
Enterprise Value | $18.11B | $15.16M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
SLAI trades at $3.34, up 7.05% today, but technical indicators signal a bearish trend with support at $3. The company reported a net loss of $33.88M in 2025, with negative profit margins and ROE. Recent news includes a reverse stock split and a going-private proposal, while the sole analyst coverage is a Hold rating.
The outlook remains highly speculative due to persistent losses and NYSE listing concerns. Risks include financial instability and execution challenges in AI infrastructure. Upside depends on successful acquisitions and product launches, but the stock is suitable only for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About SOLAI Limited
SOLAI focuses on providing innovative AI-driven software solutions. The company leverages artificial intelligence to enhance digital experiences and optimize business processes for various industries.
Read more on SLAI →
